- Home
- PHAT
as 11-19-2025 3:40pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 942.6M | IPO Year: | 2019 |
| Target Price: | $17.60 | AVG Volume (30 days): | 983.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $16.08 | Next Earning Date: | 10-30-2025 |
| Revenue: | $147,190,000 | Revenue Growth: | 460.30% |
| Revenue Growth (this year): | 218.38% | Revenue Growth (next year): | 87.14% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | PHAT | Principal Accounting Officer | Nov 3 '25 | Sell | $13.51 | 524 | $7,079.24 | 47,407 | |
| Breedlove Robert Charles | PHAT | Principal Accounting Officer | Sep 5 '25 | Sell | $12.09 | 461 | $5,573.49 | 47,407 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 days ago
Phathom Pharmaceuticals (PHAT): Forecasts Call for 75% Annual Earnings Growth as Losses Deepen
GuruFocus.com
20 days ago
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ...
Zacks
21 days ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
21 days ago
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
GuruFocus.com
22 days ago
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Report Preview: What To Expect
Simply Wall St.
23 days ago
With 51% ownership of the shares, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is heavily dominated by institutional owners
MT Newswires
a month ago
Phathom Pharmaceuticals Names Sanjeev Narula Finance, Business Chief
GlobeNewswire
a month ago
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.